A risk classification model for prioritising the management of quality issues relating to substandard medicines in Singapore
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5434
Abstract: Monitoring for substandard medicines by regulatory agencies is a key post‐market surveillance activity. It is important to prioritise critical product defects for review to ensure that prompt risk mitigation actions are taken. read more here.
Keywords: risk classification; substandard; classification model; prioritising management ... See more keywords